Fundraising Fox
/Companies
Sign in

Aspect Biosystems

Founded 2013 · 145 employees on LinkedIn · 13 known investors

Find your way into Aspect Biosystems

Sign up to see every warm intro you have to Aspect Biosystems

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Aspect Biosystems team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues. Its pipeline targets metabolic and endocrine diseases, and it partners with pharma and biotech companies to advance cell therapies to the clinic.

AI & Machine LearningBiotechLongevity

Founders & leadership

Aspect Biosystems was founded in 2013 by Tamer Mohamed, Sam Wadsworth, and Simon Beyer.

TMTamer Mohamed
Tamer MohamedFounderTamer Mohamed is Founder and CEO of Aspect Biosystems, a biotechnology company developing bioprinted tissue therapeutics that combine AI-powered bioprinting, computational design, therapeutic cells, and biomaterials for treatment of metabolic and endocrine diseases.
SWSam Wadsworth
Sam WadsworthFounderCo-founder and Chief Scientific Officer of Aspect Biosystems, a biotechnology company that uses 3D bioprinting to develop implantable tissue-based cell therapies for metabolic and endocrine diseases.
SBSimon Beyer
Simon BeyerFounder
LPLeela Paris
Leela ParisChief Technical Operations Officer
MSMike Scott
Mike ScottChief Development OfficerMike Scott is Chief Development Officer at Aspect Biosystems and has held multiple leadership roles in medical device and cell therapy development at companies including Novo Nordisk, BlueRock, ViaCyte, Edwards Lifesciences, and Orqis Medical, where he oversaw product development for treatments targeting Parkinson's disease, diabetes, heart failure, and eye diseases.
RSRay Smith
Ray SmithChief Financial Officer
KW
Konrad WalusFounder

Investors · 13

Civilization Ventures Management, Llclisted by Civilization Ventures Management, LlcTiburon · $1M – $10M

How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

InBC Investment Corp.listed by InBC Investment Corp.British Columbia · $3M – $10M

How we know: InBC Investment Corp.'s portfolio page · Not right? Tell us

JDRF T1D Fundlisted by JDRF T1D FundBoston
Page One Ventureslisted by Page One VenturesSilicon Valley
Pallasite Ventureslisted by Pallasite VenturesVancouver · $100K – $1.5M
Pangaea Ventures Us Inc.listed by Pangaea Ventures Us Inc.Vancouver · $500K – $1.5M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Radical Ventureslisted by Radical VenturesToronto · $1M – $25M

How we know: Radical Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Relentless Pursuit Partnerslisted by Relentless Pursuit PartnersVancouver

How we know: Relentless Pursuit Partners's portfolio page · Not right? Tell us

Rhino Ventureslisted by Rhino VenturesVancouver · $2M – $10M

How we know: Rhino Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Rising Tidelisted by Rising TidePacifica
6 Dimensions CapitalreportedGrand Cayman

How we know: a partner's Signal profile · Not right? Tell us

Dimension CapitalreportedSan Francisco · $1M – $10M

How we know: the VCSheet dataset · Not right? Tell us

Related companies · 3

Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
PrintBioPrintBio manufactures 3D-printed bioresorbable surgical meshes designed for hernia repair and soft tissue support. The company serves surgeons and hospitals seeking customizable mesh solutions that combine stability and flexibility while reducing infection risk.
AspectAspect provides workforce engagement management (WEM) software for enterprise teams, offering forecasting, scheduling, and performance management capabilities.

Companies working in the same space as Aspect Biosystems.

Frequently asked questions

What does Aspect Biosystems do?
Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues. Its pipeline targets metabolic and endocrine diseases, and it partners with pharma and biotech companies to advance cell therapies to the clinic.
Who founded Aspect Biosystems?
Aspect Biosystems was founded by Tamer Mohamed, Sam Wadsworth, Simon Beyer in 2013.
Who are Aspect Biosystems's investors?
Aspect Biosystems's investors include Angel Forum, Civilization Ventures Management, Llc, InBC Investment Corp., JDRF T1D Fund, Page One Ventures, Pallasite Ventures, Pangaea Ventures Us Inc., Radical Ventures and 5 more.